Drug Analysis: Bavencio - Product Image

Drug Analysis: Bavencio

  • ID: 4462234
  • Drug Pipelines
  • 64 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Bavencio is a fully human MAb targeting the PD-L1 protein. The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), regulates complex signaling pathways that affect T-cell activation, proliferation, and survival, and can induce apoptosis of tumor-specific T cells (Keir et al., 2008; Zhang et al., 2009; Zitvogel and Kroemer, 2012). By inhibiting the PD-1/PD-L1 interaction, Bavencio reduces the ability of the tumor to evade immune system targeting, and enables the activation of T cells and the adaptive immune system (Avelumab fact sheet, 2015; Pardoll, 2012). In addition, preclinical and clinical studies have suggested that drugs targeting the PD-1/PD-L1 pathway may have fewer side effects than other immune checkpoint inhibitors (Raufi and Klempner, 2015; Brahmer et al., 2012).
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Bavencio: Head and neck cancer
Bavencio: Ovarian cancer
Bavencio: Bladder cancer
avelumab: Renal cell cancer (RCC)
avelumab: Non-small cell lung cancer (NSCLC)
avelumab: Gastric cancer

List of Figures
Figure 1: Bavencio for head and neck cancer - SWOT analysis
Figure 2: Drug assessment summary of Bavencio for SCCHN
Figure 3: Drug assessment summary of Bavencio for SCCHN
Figure 4: Bavencio sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 5: Bavencio for ovarian cancer - SWOT analysis
Figure 6: Drug assessment of Bavencio for ovarian cancer
Figure 7: Drug assessment of Bavencio for ovarian cancer
Figure 8: Bavencio for urothelial bladder cancer - SWOT analysis
Figure 9: Drug assessment summary for Bavencio in urothelial bladder cancer
Figure 10: Drug assessment summary for Bavencio in urothelial bladder cancer
Figure 11: Avelumab for renal cell cancer - SWOT analysis
Figure 12: Drug assessment summary of avelumab for renal cell cancer
Figure 13: Drug assessment summary of avelumab for renal cell cancer
Figure 14: Avelumab for non-small cell lung cancer - SWOT analysis
Figure 15: Drug assessment summary for avelumab in non-small cell lung cancer
Figure 16: Drug assessment summary for avelumab in non-small cell lung cancer
Figure 17: Avelumab for gastric cancer - SWOT analysis
Figure 18: Drug assessment summary for avelumab in gastric cancer
Figure 19: Drug assessment summary for avelumab in gastric cancer

List of Tables
Table 1: Bavencio drug profile
Table 2: Bavencio Phase III trials in head and neck cancer
Table 3: Bavencio early-phase data in head and neck cancer
Table 4: Bavencio sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 5: Bavencio patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 6: Bavencio drug profile
Table 7: Bavencio Phase III trials in ovarian cancer
Table 8: Overview of Phase I data for Bavencio in ovarian cancer
Table 9: Bavencio drug profile
Table 10: Bavencio pivotal trial data in urothelial bladder cancer
Table 11: Bavencio ongoing late-phase trials in urothelial bladder cancer
Table 12: Avelumab drug profile
Table 13: Avelumab Phase III trial in renal cell cancer
Table 14: Avelumab drug profile
Table 15: Avelumab Phase III trials in non-small cell lung cancer
Table 16: Avelumab early-phase data in non-small cell lung cancer
Table 17: Avelumab drug profile
Table 18: Avelumab late-phase trials in gastric cancer
Table 19: Avelumab early-phase data in gastric cancer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll